Skip to main content

Table 1 Patient’s characteristics and the level of clinical indicators

From: Serum BPI as a novel biomarker in asthma

 Uncontrolled asthma (n = 39)Controlled asthma (n = 18)Controlled (n = 35)
Age50.51 ± 12.1342.17 ± 16.0648.13 ± 8.08
Male sex (%)35.9044.4434.29
BMI (kg/m2)22.09 ± 3.0722.56 ± 5.0322.55 ± 3.00
Smoker (%)38.4633.3325.71
Allergic history (%)24.3222.2214.28
Blood
 Eosinophils counts0.33 ± 0.41 * 109/L*0.28 ± 0.19 * 109/L0.15 ± 0.61 * 109/L
 Neutrophils counts5.71 ± 2.86 * 109/L*#3.65 ± 1.08 * 109/L3.59 ± 1.09 * 109/L
 Total IgE (IU/mL)367.90 ± 461.46235.76 ± 197.31
 FeNO (ppb)46.67 ± 55.8030.10 ± 21.41
 Serum BPI (ng/mL)18.10 ± 13.48*,#12.83 ± 6.04*6.00 ± 2.27
 hs-CRP8.59 ± 14.888.82 ± 15.64
 FEV1% pred63.84 ± 27.05#72.78 ± 25.79
  1. Data are presented as mean ± SD. Data in the controlled and uncontrolled asthma groups were collected before inhaled corticosteroid (ICS) therapy. *p < 0.05 Comparisons were made among the three groups
  2. IgE immunoglobulin E, BPI bactericidal/permeability increasing protein, FEV1% predicted forced expiratory volume in one second as percentage of predicted volume
  3. * p < 0.05 versus healthy control group
  4. #p < 0.05 versus controlled asthma group